Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Prohibited at all times
2026 S4.1: prohibited at all times. Specified. [1]
S4.1 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
Regulatory and market context
A 2018 FDA warning letter identified a product labelled with arimistane, Androsta-3,5-diene-7,17-dione. FDA stated that the product did not meet the dietary-supplement definition and was an unapproved new drug. This supports historical labelled-product exposure, not proof of the contents of every product using the name. [2]
- An enforcement letter is not a clinical trial or a modern batch assay.
What remains uncertain
- Human therapeutic benefit and a reliable clinical safety profile remain unverified. Do not confuse arimistane with anastrozole.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · Relevant official full-text sections opened
Printed pp. 3, 9–12: introduction, S3, S4 and S5 as applicable
- FDA VMI Sports warning letter, 2018 ↗Accessed 2026-11-10 · Relevant document text opened
Relevant cited sections
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.